Cargando…
In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice
CRISPR/Cas9 screening approaches are powerful tool for identifying in vivo cancer dependencies. Hematopoietic malignancies are genetically complex disorders in which the sequential acquisition of somatic mutations generates clonal diversity. Over time, additional cooperating mutations may drive dise...
Autores principales: | Li, Bin E., Li, Grace Y., Cai, Wenqing, Zhu, Qian, Seruggia, Davide, Fujiwara, Yuko, Vakoc, Christopher R., Orkin, Stuart H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506108/ https://www.ncbi.nlm.nih.gov/pubmed/37428871 http://dx.doi.org/10.1182/bloodadvances.2022009455 |
Ejemplares similares
-
In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies
por: Mercier, Francois E., et al.
Publicado: (2022) -
Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML
por: Nguyen, Nam H. K., et al.
Publicado: (2022) -
Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
por: Kramer, Michael H., et al.
Publicado: (2022) -
Coping strategies in patients with acute myeloid leukemia
por: Amonoo, Hermioni L., et al.
Publicado: (2022) -
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)